JPY1,460.00
1.46% day before yesterday
Tokyo, May 02, 08:15 am CET
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Astellas Pharma Stock price

JPY1,458.00
+54.00 3.85% 1M
-323.50 18.16% 6M
-76.50 4.99% YTD
-100.00 6.42% 1Y
-502.00 25.61% 3Y
-325.00 18.23% 5Y
-417.00 22.24% 10Y
Tokyo, Closing price Fri, May 02 2025
+19.00 1.32%
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Key metrics

Market capitalization JPY2.61t
Enterprise Value JPY3.25t
P/E (TTM) P/E ratio 51.44
EV/FCF (TTM) EV/FCF 19.76
EV/Sales (TTM) EV/Sales 1.70
P/S ratio (TTM) P/S ratio 1.37
P/B ratio (TTM) P/B ratio 1.72
Dividend yield 5.35%
Last dividend (FY26) JPY78.00
Revenue growth (TTM) Revenue growth 19.25%
Revenue (TTM) Revenue JPY1.91t
EBIT (operating result TTM) EBIT JPY255.67b
Free Cash Flow (TTM) Free Cash Flow JPY164.61b
Cash position JPY188.37b
EPS (TTM) EPS JPY28.34
P/E forward 16.69
P/S forward 1.33
EV/Sales forward 1.66
Show more

Is Astellas Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,786 stocks worldwide.

Astellas Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Astellas Pharma forecast:

5x Buy
38%
7x Hold
54%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Astellas Pharma forecast:

Buy
38%
Hold
54%
Sell
8%

Financial data from Astellas Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,912,323 1,912,323
19% 19%
100%
- Direct Costs 485,968 485,968
24% 24%
25%
1,426,355 1,426,355
18% 18%
75%
- Selling and Administrative Expenses 643,900 643,900
11% 11%
34%
- Research and Development Expense 327,651 327,651
11% 11%
17%
454,804 454,804
35% 35%
24%
- Depreciation and Amortization 199,132 199,132
26% 26%
10%
EBIT (Operating Income) EBIT 255,672 255,672
44% 44%
13%
Net Profit 50,747 50,747
293% 293%
3%

In millions JPY.

Don't miss a Thing! We will send you all news about Astellas Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Naoki Okamura
Founded 1923
Website www.astellas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today